From the Guidelines
The recommended intramuscular (IM) dose of Kenalog (triamcinolone acetonide) is 60 mg, as supported by an uncontrolled trial where all patients had at least 50% clinical improvement on a VAS after one or two intramuscular injections of triamcinolone acetonide 60 mg within 14 days without any significant side effect 1. This dose is used to treat various inflammatory conditions, including acute crystal-induced arthritis.
- The medication should be injected deep into the gluteal muscle using proper aseptic technique.
- Patients should be monitored for potential side effects including injection site reactions, elevated blood glucose, mood changes, and adrenal suppression with long-term use.
- The duration of action is typically 1 to 6 weeks.
- Lower doses should be considered for elderly patients, those with comorbidities, or when used for extended periods to minimize systemic side effects. The anti-inflammatory effect of triamcinolone occurs because it suppresses the migration of polymorphonuclear leukocytes and reverses increased capillary permeability, thereby reducing inflammation 1.
- The use of Kenalog (triamcinolone acetonide) is particularly useful and safe for the treatment of acute monoarticular or oligoarticular microcrystalline synovitis, as well as for patients with polyarticular attacks who are contraindicated or intolerant of NSAIDs 1.
From the FDA Drug Label
KENALOG-40 40 mg per 10 mL Injectable Suspension For intramuscular or intra-articular use only Studies indicate that following a single intramuscular dose of 60 mg to 100 mg of triamcinolone acetonide, adrenal suppression occurs within 24 to 48 hours and then gradually returns to normal, usually in 30 to 40 days.
The recommended intramuscular (IM) dose of Kenalog (triamcinolone) is between 60 mg to 100 mg 2.
From the Research
Kenalog IM Dose
The recommended intramuscular (IM) dose of Kenalog (triamcinolone) is not explicitly stated in the provided studies. However, the following information can be gathered:
- The studies focus on the efficacy and pharmacology of triamcinolone acetonide, but do not provide a specific recommended IM dose 3, 4, 5.
- One study compares the efficacy of intra-articular injection of 10 mg and 20 mg triamcinolone for rheumatoid arthritis of the wrist, but this is not directly related to IM dosing 5.
- Another study reports a case of immediate hypersensitivity reaction to triamcinolone, but does not discuss IM dosing 6.
- A study on the impact of adverse events associated with medications in the treatment and prevention of rheumatoid arthritis mentions glucocorticoids, but does not provide specific information on Kenalog IM dosing 7.
Key Points
- The provided studies do not offer a clear recommendation for the IM dose of Kenalog.
- The studies focus on various aspects of triamcinolone acetonide, including its pharmacology, efficacy, and potential adverse effects.
- Further research or consultation of other sources may be necessary to determine the recommended IM dose of Kenalog.